1-4 of 4
Pieter Fokko van Loo
Close
Sort by
Journal Articles

Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML

Pieter Fokko Van Loo, PhD, Robert Doornbos, PhD, Harry Dolstra, PhD, Setareh Shamsili, MD PhD, Lex Bakker, PhD
Journal: Blood
Blood (2015) 126 (23): 325.
https://doi.org/10.1182/blood.V126.23.325.325
Published: 2015
Journal Articles

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice

Laurens P. Kil, Marjolein J. W. de Bruijn, Menno van Nimwegen, Odilia B. J. Corneth, Jan Piet van Hamburg, Gemma M. Dingjan, Friedrich Thaiss, Guus F. Rimmelzwaan, Dirk Elewaut, Dianne Delsing, Pieter Fokko van Loo, Rudi W. Hendriks
Journal: Blood
Blood (2012) 119 (16): 3744–3756.
https://doi.org/10.1182/blood-2011-12-397919
Published: 2012
Includes: Supplemental data
Journal Articles

Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway

Van B. T. Ta, Marjolein J. W. de Bruijn, Petra J. ter Brugge, Jan Piet van Hamburg, Hans J. A. Diepstraten, Pieter Fokko van Loo, Rogier Kersseboom, Rudi W. Hendriks
Journal: Blood
Blood (2010) 115 (7): 1385–1393.
https://doi.org/10.1182/blood-2009-05-222166
Published: 2010
Includes: Supplemental data
Journal Articles

Impaired hematopoiesis in mice lacking the transcription factor Sp3

Pieter Fokko van Loo, Peter Bouwman, Kam-Wing Ling, Sabine Middendorp, Guntram Suske, Frank Grosveld, Elaine Dzierzak, Sjaak Philipsen, Rudolf W. Hendriks
Journal: Blood
Blood (2003) 102 (3): 858–866.
https://doi.org/10.1182/blood-2002-06-1848
Published: 2003